ClinicalTrials.gg
CompletedNCT02279966Updated Feb 28, 2017

Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine 10 mg and Paroxetine 20 mg in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed at 18 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
34th of 54
152 · median 413
Started
2014
with 3 others
Phase 3
31 of 54
1 open now
Registered
25th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 34th largest by enrollment, is one of 4 that started in 2014, is one of 31 in phase 3, and was the 25th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To assess the efficacy of acute treatment with 10 mg/day vortioxetine versus placebo on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning, attention) in working patients with major depressive disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has MDD, diagnosed according to , 4th edition, Text Revision (DSM-IV-TR™) recurrent major depressive disorder (MDD) (classification 296.3x).
  • The patient has a MADRS total score ≥26.
  • The patient has had the current major depressive episode (MDE) for ≥3 months.
  • The patient is aged ≥18 and ≤65 years.
  • The patient is employed full or part-time (defined as minimum 50% full time working hours per week). Part time work should not be due to a medical or mental illness other than MDD.
  • The patient has been in the current job/position for at least 3 months.
  • The patient has no plans to change jobs or retire within treatment period.
  • The patient is not on a sick leave, and at the Screening and Randomisation Visits, there are no plans to send the patient on a sick leave.
  • The patient is not receiving disability benefits.

Exclusion criteria

Exclusion criteria:

  • The patient has a score ≥70 on the DSST (number of correct symbols) at the Baseline Visit.
  • The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit.
  • The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • The patient is diagnosed with reading disability (dyslexia).
  • The patient has a history of lack of response to previous adequate treatment with vortioxetine or paroxetine.
  • The patient has any current psychiatric disorder or Axis I disorder (according to ™ criteria) other than MDD, as assessed using MINI.
  • The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of current episode (DSM-IV-TR™ criteria).
  • The patient has borderline, schizotypal, schizoid, paranoid, or histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
  • The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Vortioxetine 10 mg

    daily, encapsulated, orally

    Drug: Vortioxetine 10 mg

  • Other
    Paroxetine 20 mg (active reference)

    daily, encapsulated, orally

    Drug: Paroxetine 20 mg

  • Placebo comparator
    Placebo

    capsules, orally

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Digit Symbol Substitution Test (DSST): number of correct symbols

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Trail Making Test (TMT) score: TMT-A; speed of processing

    Time frame: Baseline to Week 8

  2. Change in TMT-B; executive functioning

    Time frame: Baseline to Week 8

  3. Change in reaction time score: Choice Reaction Time (CRT); attention

    Time frame: Baseline to Week 8

  4. Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed)

    Time frame: Baseline to Week 8

  5. Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning

    Time frame: Baseline to Week 8

  6. Change in STROOP: congruent score; speed of processing

    Time frame: Baseline to Week 8

  7. Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score

    Time frame: Baseline to Week 8

  8. Change in Montgomery and Asberg Depression Rating Scale (MADRS) total score

    Time frame: Baseline to Week 8

  9. Change in Clinical Global Impression - Severity of Illness (CGI-S)

    Time frame: Baseline to Week 8

  10. Clinical Global Impression - Global Improvement (CGI-I) score

    Time frame: Week 8

  11. Change in the Functioning Assessment Short Test (FAST) total score

    Time frame: Baseline to Week 8

  12. Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score

    Time frame: Baseline to Week 8

07

Study locations

18 sites
  • EE001
    Tallinn, Estonia
  • EE002
    Tallinn, Estonia
  • EE004
    Voru, Estonia
  • FI002
    Helsinki, Finland
  • FI003
    Helsinki, Finland
  • FI001
    Kuopio, Finland
  • FI008
    Oulu, Finland
  • FI007
    Tampere, Finland
  • DE002
    Berlin, Germany
  • DE001
    Bielefeld, Germany
  • DE003
    Frankfurt, Germany
  • DE007
    Frankfurt, Germany
  • DE008
    Schwerin, Germany
  • LT002
    Kaunas, Lithuania
  • LT006
    Palanga, Lithuania
  • LT003
    Silute, Lithuania
  • LT001
    Vilnius, Lithuania
  • LT005
    Vilnius, Lithuania
08

References and documents

Publications

  • Christensen MC, Sluth LB, McIntyre RS. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings. J Affect Disord. 2019 Feb 15;245:508-516. doi: 10.1016/j.jad.2018.11.034. Epub 2018 Nov 5. PubMed 30439678 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Feb 2016, 16 months.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2014
First posted
Oct 31, 2014
StartActual
Oct 2014
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02279966
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 31, 2014
Start date
Oct 2014
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Feb 28, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion